LAM Pharmaceutical, Corp., a biomedical company, has entered into a strategic agreement with Benchmark Capital Consulting, Inc. a subsidiary of Benchmark Global Capital Group to explore product distribution and strategic alliance opportunities in China.

Benchmark Global Capital Group's China subsidiary is one of the leading U.S. based investment and consulting firms in China. Through its Asian headquarters located in Beijing, Benchmark provides comprehensive market entry, management consulting, and investment banking related services to its Chinese and international clients. Benchmark's strategic partners in China include the Chinese Medical Foundation, China Hewlett Packard, Ernst & Young and many others.

Joseph Slechta, LAM's president & chief operating officer commented: "Our decision to enter the Chinese market is consistent with our strategy, which is to establish commercial and financial alliances for our L.A.M. IPM wound gel and other products in key international locations. We look forward to working with Benchmark and are excited about the opportunity to enhance the Company's performance and to build long-term shareholder value."

Sarah Wei, Benchmark's chief representative in Beijing commented: "We have extensive experience in successfully introducing new products/services to the Chinese markets through our established networks. Before we took on this project, we conducted thorough market research. We visited patients, doctors and government officials about the product's market potentials. We are surprised and excited to discover that there are currently no effective products in China for treating diabetic wounds and ulcers. China has the world's largest number of diabetics, almost 65 million patients. The market potential for this product is enormous. We look forward to introducing this wonderful product to the Chinese people."